FDA Approves Epioxa: A New Topical Treatment Option for Keratoconus Patients

Good news for the inherited retinal disease (IRD) community and beyond! Glaukos Corporation announced on October 20, 2025, that the U.S. Food and Drug Administration (FDA) has approved its new drug therapy, Epioxa HD/Epioxa, for the treatment of keratoconus. This approval marks a significant advancement, as Epioxa is the first FDA-approved corneal cross-linking treatment that is incision-free and does not require the removal of the corneal epithelium.

This development is particularly relevant for individuals and families affected by IRDs, as advancements in broader ophthalmology can often pave the way for new diagnostic tools, treatment approaches, and a deeper understanding of eye health that benefits the entire vision loss community. While keratoconus is distinct from inherited retinal diseases, innovations in corneal treatments highlight the ongoing progress in addressing various forms of vision impairment and underscore the importance of continued research and development in eye care.

Key Facts About Epioxa Approval

Epioxa is a topical drug therapy designed to treat keratoconus, a progressive corneal disorder that causes thinning and weakening of the cornea, potentially leading to visual impairment and, in severe cases, corneal transplantation.

  • Incision-Free Treatment: Unlike previous methods, Epioxa does not require the removal of the corneal epithelium (the outer layer of the cornea), making it a less invasive option.
  • Topical Application: The therapy involves two oxygen-enriched topical formulations—Epioxa HD and Epioxa—applied sequentially and activated by UV light.
  • Clinical Trial Success: The FDA approval was based on results from two Phase 3 pivotal trials involving over 400 patients, which demonstrated the therapy's safety, tolerability, and effectiveness.
  • Improved Patient Experience: This new approach is expected to significantly improve patient comfort and minimize recovery time compared to traditional cross-linking procedures.

What This Means for Patients and Families

The approval of Epioxa offers a new standard of care for patients suffering from keratoconus. The less invasive nature of this topical treatment means reduced discomfort during the healing process and a quicker recovery, which can be a significant benefit for patients, many of whom are diagnosed at 30 years old or younger. Keratoconus has historically been underrecognized and undertreated, and this new therapy could expand access to effective treatment.

Looking Ahead

Glaukos anticipates that Epioxa will be commercially available in early 2026. The company plans to increase investments in patient awareness, education, and access, including patient access support programs, a co-pay assistance program, and awareness campaigns aimed at earlier screening and diagnosis. This focus on accessibility and early intervention is crucial for ensuring that more individuals who could benefit from this treatment can receive it.

This FDA approval represents a positive step forward in ophthalmology, offering hope for improved outcomes and quality of life for those affected by keratoconus.